Precision BioSciences Q2 2024 net income $32.7M; cash $123.6M; HBV program on track for IND in 2024

PRECISION BIOSCIENCES INC

2024-Q2 EPS reported $6.81 revenue$67,482,000

Net income from continuing ops $32.7M vs loss $11.9M YoY; revenue $49.9M (+$30.1M) from Prevail termination.
Cash $123.6M; expected runway into H2 2026.
PBGENE-HBV on track for IND/CTA submission in 2024; PBGENE-PMM targeted for 2025.
Regained control of three preclinical programs from Prevail (DMD, liver, CNS) for internal/partner development.
Entered into $22.5M term loan with Banc of California (maturity June 2027).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.